Optimizing engraftment - Source and dose of stem cells

Seminars in Hematology

Volumn 39, Issue 1, 2002, Pages 3-14

  Schmitz, Norbert ^a   Barrett, John ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA; MORTALITY; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL RATE; UMBILICAL CORD BLOOD;

EID: 0036141451     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2002.29245     Document Type: Article

References (87)

1. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma
2. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
3. Mega-dose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
4. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: Graft-versus-host disease, donor type, cytomegalovirus infections and cell dose
5. + cell dose predicts relapse and survival after T-cell-depleted HLA identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies
6. Non-myeloablative stem cell transplants
7. Effect of nucleated marrow cell dose on relapse and survival in identical twin transplants for leukemia
8. Transplantation filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: A prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerism
9. Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers
10. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor
11. A randomized, double-blind trial of filgrastim (granulocyte colony stimulating factor) versus placebo following allogeneic blood stem cell transplantation
12. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Société Francaise de Greffe de Moelle
13. Long-term follow-up of high-risk allogeneic peripheral blood stem cell transplant recipients: Graft-versus-host disease and transplant-related mortality
14. Human umbilical cord blood as a potential source of transplantable human hematopoietic stem/progenitor cells
15. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: A retrospective single centre analysis
16. Peripheral blood progenitor cells: A replacement for marrow transplantation?
17. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T-cell antibodies with narrow specificities
18. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
19. Evidence that umbilical cord blood contains a higher frequency of HLA-class-II specific alloreactive T cells than adult peripheral blood. A limiting dilution analysis
20. + purified cells from human cord blood and bone marrow
21. Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: Changing impact of risk factors
22. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow
23. Rapidly mobilizable stem cells. Do they belong to a special subpopulation?
24. Allogeneic peripheral blood progenitor cell transplantation in an murine model: Evidence for an improved graft-versus-leukaemia effect
25. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling
26. Outcome of cord-blood transplantation from related and unrelated donors
27. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor
28. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support
29. Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow
30. Transplantation of megadoses of purified haploidentical stem cells
31. Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes
32. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow
33. Granulocyte colony-stimulating factor downregulates allogeneic immune responses by posttranscriptional inhibition of tumor necrosis factor-alpha production
34. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts
35. CD34: Structure, biology, and clinical utility
36. +) in the blood of normal donors
37. Hematopoietic engraftment and survival in adult recipients of umbilical cord blood from unrelated donors
38. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies
39. + cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies
40. + cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells
41. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: Graft progenitor cell content is a better predictor than nucleated cell quantity
42. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure enhancing stem cell dose
43. +) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia
44. + cells predict outcome in patients with haematological malignancies undergoing T-cell depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back
45. CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftment
46. + cells in cord blood
47. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow
48. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft versus-host disease
49. Importance of bone marrow cell dose in bone marrow transplantation
50. Hematopoietic recovery after allogeneic blood stem cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies
51. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors
52. Allogeneic blood and bone marrow stem-cell transplantation in haematological malignant diseases: A randomised trial
53. Primitive long term culture initiating cells (LTC-ICs) in granulocyte colonystimulating factor mobilized peripheral blood progenitor cells have similar potential for ex vivo expansion as primitive LTC-ICs in steady state bone marrow
54. Allogeneic transplantation for advanced leukemia: Improved shirt-term outcome with blood stem cell grafts and tacrolimus
55. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation
56. Engraftment of hematopoietic stem cells in nonmyeloablated and myeloablated hosts
57. + cell transplants
58. Proliferative and cytotoxic responses of human cord blood T lymphocytes following allogeneic stimulation
59. Comparison of outcomes of unrelated bone marrow and umbilical cord transplants in children with acute leukemia
60. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry working committee on alternative donor and stem cell sources
61. Immune function of cord blood before and after transplantation
62. + blood cells
63. Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells
64. Peripheral blood stem cell transplantation from unrelated donors: A comparison with marrow transplantation
65. Outcomes among 562 recipients of placental-blood transplants from unrelated donors
66. Allogeneic blood cell transplants for haematological malignancy: Preliminary comparison of outcomes with bone marrow transplantation
67. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)
68. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients
69. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: A case controlled study
70. Therapeutic relevance of CD 34 cell dose in blood cell transplantation for cancer therapy
71. Unrelated donor marrow transplantation for acute myeloid leukemia: An update of the Seattle experience
72. A Canadian randomized study comparing peripheral blood (PB) and bone marrow (BM) in patients undergoing matched sibling transplants for myeloid malignancies
73. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation
74. + cells/kg be considered the minimum threshold?
75. Chronic graft-versushost-disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study
76. + cells from umbilical cord blood, granulocyte colony-stimulating factor-mobilized peripheral blood and adult human bone marrow
77. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
78. + subsets, colonyforming cells and cobblestone area forming cells in cord blood and marrow allografts
79. + cells
80. Reduced risk of persisting cytomegalovirus pp 65 antigenemia and cytomegalovirus interstitial pneumonias following allogeneic PBSCT
81. Influence of cell dose and graft-versus -host reactivity on rejection rates after allogeneic bone marrow transplantation
82. +) selected cells from peripheral blood from HLA-identical siblings
83. Human G-CSF-mobilized CD34-positive peripheral blood progenitor cells can stimulate allogeneic T-cell responses: Implications for graft rejection in mismatched transplantation
84. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies
85. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors analysis of engraftment and acute graft-versus-host disease
86. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID repopulating cell assay